The AHA has published a scientific statement regarding the screening, diagnosis, and management of hypertriglyceridemia in pediatric patients.
—In a new U.S.-based study, a causal relationship was found between risk of abdominal aortic aneurysm (AAA) and elevation in triglyceride-rich lipoproteins and triglyceride metabolism-related proteins ...
Both doses of olezarsen significantly reduced triglyceride levels at 6 months compared with placebo (placebo-adjusted reduction, 50mg: 58%; 80mg: 61%; P .0001). Topline data were announced from a ...
A Prescription Drug User Fee Act target date of June 30, 2026 has been assigned to the application. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental New Drug ...
—Analysis of CD4+ and CD8+ T cells from patients with varying lipid levels suggests new role for hypertriglyceridemia in CVD risk. Moderate—but not severe—hypertriglyceridemia has been shown to be ...
NEW ORLEANS — When added to standard lipid-lowering therapy, olezarsen, a drug approved in 2024 for patients with familial chylomicronemia syndrome, significantly lowered triglycerides and reduced the ...
CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results